Evidence map›Paper›PMID 35452553›Full record

ArticleMolecular carcinogenesis2022

Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.

Komal Raina, Rama Kant, Ram R Prasad, Kushal Kandhari, Munendra Tomar, Neha Mishra, Robin Kumar, Jennifer T Fox, Shizuko Sei, Robert H Shoemaker and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular carcinogenesis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Komal RainaDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Rama KantDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Ram R PrasadDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Kushal KandhariDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-8323-7278
Munendra TomarDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Neha MishraDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Robin KumarDepartment of Pharmaceutical Sciences, South Dakota State University, Brookings, South Dakota, USA.
Jennifer T FoxDivision of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Shizuko SeiDivision of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Robert H ShoemakerDivision of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Yu ChenDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Paul MaroniDepartment of Surgery, Division of Urology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Chapla AgarwalDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Rajesh AgarwalDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-9455-0235

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0M
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7M
NCI NIH HHS HHSN261201200038INCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA193837
6 · The paper itself

Abstract

In the present study, we performed a comparative stage-specific pathological and molecular marker evaluation of TMPRSS2-ERG fusion and PTEN loss-driven (TMPRSS2-ERG. Pten

Indexed as

AdenocarcinomaProstatic NeoplasmsAnimalsCarcinogenesisHumansMaleMiceOncogene Proteins, FusionProstateSerine EndopeptidasesTranscriptional Regulator ERGERG protein, humanOncogene Proteins, FusionSerine EndopeptidasesTMPRSS2-ERG fusion protein, humanTMPRSS2 protein, humanTranscriptional Regulator ERGERGHi-Myc miceprostate cancerprostatic intraepithelial neoplasiaTMPRSS2-ERG fusion

Identifiers

PMID35452553
PMCPMC10007524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.